Vitamin D vs placebo/no treatment: Clinical relapse
Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Vitamin D (all doses) vs placebo/no treatment Clinical relapse at end of study (26–52) weeks · people with active or inactive inflammatory bowel disease of any age Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty). Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane Headline outcomes only | RR 0.57 [0.34, 0.96] | 3 studies · 310 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.